SARS-CoV-2 suppression depending on the pH of graphene oxide nanosheets

Islam, M. Saidul; Fukuda, Masahiro; Hossain, Md. Jakir; Rabin, Nurun Nahar; Tagawa, Ryuta; Nagashima, Mami; Sadamasu, Kenji; Yoshimura, Kazuhisa; Sekine, Yoshihiro; Ikeda, Terumasa; Hayami, Shinya

doi:10.1039/d3na00084b

Cited by 9 publications

(7 citation statements)

References 28 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plaque assays were conducted to measure the antiviral efficiency of the GO-anchored mask against the BA.5 variant, as reported previously. 10,11,[15][16][17][18][19] The details about the experimental procedure are shown in the ESI. †…”

Section: Methodsmentioning

confidence: 99%

“…10 Moreover, the increment in the hydroxyl functional groups at a higher pH of GO has more anti-SARS-CoV-2 activity than that of acidic or neutral conditions. 11 Some other recent works also provide the theoretical and practical possibility of GO-based materials as a platform to combat current and future pandemics. [12][13][14] In the present work, we demonstrate the SARS-CoV-2 inactivation of GOanchored filters and compare the inactivation efficiency with the commercially available face mask.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 inactivation: assessing the efficacy of GO-anchored filters versus various commercial masks

Islam,

Rabin,

Begum

et al. 2024

RSC Appl. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 inactivation: assessing the efficacy of GO-anchored filters versus various commercial masks

Islam,

Rabin,

Begum

et al. 2024

RSC Appl. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…Plaque assay was performed as previously described 21,31,46,56 . One day before infection, 1 × 10 5 VeroE6/TMPRSS2 cells were seeded into 24 well plate and infected with SARS-CoV-2 (50,000, 5000, 500, and 50 TCID 50 respectively) at 37 ◦ C for 1 hour.…”

Section: Methodsmentioning

confidence: 99%

“…Virus propagation was performed as previously described 27,54,56 . Briefly, VeroE6/TMPRSS2 cells (5 × 10 6 cells) were seeded in a T-75 flask the day before infection.…”

Section: Virus Preparationmentioning

confidence: 99%

Virological characteristics correlating with SARS-CoV-2 spike protein fusogenicity

Begum,

Ichihara,

Takahashi

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike (S) protein is essential in mediating membrane fusion of the virus with the target cells. Several reports demonstrated that SARS-CoV-2 S protein fusogenicity is reportedly closely associated with the intrinsic pathogenicity of the virus determined using hamster models. However, the association between S protein fusogenicity and other virological parameters remains elusive. In this study, we investigated the virological parameters of eleven previous variants of concern (VOCs) and variants of interest (VOIs) correlating with S protein fusogenicity. S protein fusogenicity was found to be strongly correlated with S1/S2 cleavage efficiency and plaque size formed by clinical isolates. However, S protein fusogenicity was less associated with pseudoviral infectivity, pseudovirus entry efficiency, and viral replication kinetics. Taken together, our results suggest that S1/S2 cleavage efficiency and plaque size could be potential indicators to predict the intrinsic pathogenicity of newly emerged SARS-CoV-2 variants.

show abstract

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) D614G-bearing B.1.1 variant (strain TKYT41838, GenBank accession no. LC606020) was propagated as previously described [40,41]. Briefly, VeroE6/TMPRSS2 cells (5 × 10 6 cells) were seeded in a T-75 flask the day before infection.…”

Section: Sars-cov-2 D614g-bearing B11 Variant Preparationmentioning

confidence: 99%

A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24

Nyame,

Togami,

Yoshida

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

The introduction of combined antiretroviral therapy (cART) has greatly improved the quality of life of human immunodeficiency virus type 1 (HIV-1)-infected individuals. Nonetheless, the ever-present desire to seek out a full remedy for HIV-1 infections makes the discovery of novel antiviral medication compelling. Owing to this, a new late-stage inhibitor, Lenacapavir/Sunlenca, an HIV multi-phase suppressor, was clinically authorized in 2022. Besides unveiling cutting-edge antivirals inhibiting late-stage proteins or processes, newer therapeutics targeting host restriction factors hold promise for the curative care of HIV-1 infections. Notwithstanding, bone marrow stromal antigen 2 (BST2)/Tetherin/CD317/HM1.24, which entraps progeny virions is an appealing HIV-1 therapeutic candidate. In this study, a novel drug screening system was established, using the Jurkat/Vpr-HiBiT T cells, to identify drugs that could obstruct HIV-1 release; the candidate compounds were selected from the Ono Pharmaceutical compound library. Jurkat T cells expressing Vpr-HiBiT were infected with NL4-3, and the amount of virus release was quantified indirectly by the amount of Vpr-HiBiT incorporated into the progeny virions. Subsequently, the candidate compounds that suppressed viral release were used to synthesize the heterocyclic compound, HT-7, which reduces HIV-1 release with less cellular toxicity. Notably, HT-7 increased cell surface BST2 coupled with HIV-1 release reduction in Jurkat cells but not Jurkat/KO-BST2 cells. Seemingly, HT-7 impeded simian immunodeficiency virus (SIV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) release. Concisely, these results suggest that the reduction in viral release, following HT-7 treatment, resulted from the modulation of cell surface expression of BST2 by HT-7.

show abstract

SARS-CoV-2 suppression depending on the pH of graphene oxide nanosheets

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivation of pH-dependent graphene oxide (GO) nanosheets is presented. The observed virus inactivation using authentic virus (Delta varient) and different GO dispersion at...

Cited by 9 publications

References 28 publications

SARS-CoV-2 inactivation: assessing the efficacy of GO-anchored filters versus various commercial masks

SARS-CoV-2 inactivation: assessing the efficacy of GO-anchored filters versus various commercial masks

Virological characteristics correlating with SARS-CoV-2 spike protein fusogenicity

A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24

Contact Info

Product

Resources

About